Status:
ACTIVE_NOT_RECRUITING
BS01 in Patients With Retinitis Pigmentosa
Lead Sponsor:
Bionic Sight LLC
Conditions:
Retinitis Pigmentosa
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Eligibility Criteria
Inclusion
- Confirmed diagnosis of retinitis pigmentosa
- At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.
Exclusion
- Prior receipt of any AAV gene therapy product
- Large amplitude nystagmus
Key Trial Info
Start Date :
February 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2029
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04278131
Start Date
February 6 2020
End Date
December 30 2029
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Jersey Retina
Teaneck, New Jersey, United States, 07666